Amgen, Inc. (NASDAQ:AMGN) – Investment analysts at Jefferies Group cut their Q4 2017 earnings per share (EPS) estimates for shares of Amgen in a report issued on Sunday. Jefferies Group analyst E. Yang now expects that the medical research company will post earnings of $2.80 per share for the quarter, down from their prior estimate of $2.81. Jefferies Group currently has a “Hold” rating and a $180.00 target price on the stock.
AMGN has been the topic of a number of other research reports. Robert W. Baird reissued a “neutral” rating and set a $165.00 target price on shares of Amgen in a research report on Friday, March 17th. Cann reissued an “outperform” rating and set a $189.00 target price on shares of Amgen in a research report on Tuesday, February 28th. Oppenheimer Holdings Inc. set a $175.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, February 14th. Royal Bank of Canada set a $190.00 target price on shares of Amgen and gave the company a “buy” rating in a research report on Tuesday, January 31st. Finally, Credit Suisse Group AG reissued a “hold” rating and set a $178.00 target price on shares of Amgen in a research report on Sunday, February 5th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $186.89.
TRADEMARK VIOLATION NOTICE: This story was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/06/16/equities-analysts-issue-forecasts-for-amgen-inc-s-q4-2017-earnings-amgn-updated-updated.html.
Amgen (NASDAQ:AMGN) opened at 154.60 on Tuesday. Amgen has a 52 week low of $133.64 and a 52 week high of $184.21. The company’s 50-day moving average price is $161.21 and its 200-day moving average price is $159.24. The company has a market capitalization of $113.69 billion, a P/E ratio of 14.68 and a beta of 1.15.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, April 26th. The medical research company reported $3.15 EPS for the quarter, topping the Zacks’ consensus estimate of $3.00 by $0.15. The firm had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.60 billion. Amgen had a return on equity of 29.42% and a net margin of 33.59%. The firm’s revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.90 EPS.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Shareholders of record on Wednesday, May 17th will be paid a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a yield of 2.98%. The ex-dividend date of this dividend is Monday, May 15th. Amgen’s payout ratio is 44.92%.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares in the company, valued at approximately $3,738,641.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.20% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Mizuho Trust & Banking Co. Ltd. boosted its position in Amgen by 1.0% in the third quarter. Mizuho Trust & Banking Co. Ltd. now owns 1,229,739 shares of the medical research company’s stock valued at $205,133,000 after buying an additional 11,665 shares in the last quarter. BRC Investment Management LLC purchased a new position in Amgen during the third quarter valued at about $6,852,000. Vicus Capital purchased a new position in Amgen during the third quarter valued at about $327,000. Spero Smith Investment Advisers Inc. OH boosted its position in Amgen by 16.7% in the third quarter. Spero Smith Investment Advisers Inc. OH now owns 1,743 shares of the medical research company’s stock valued at $291,000 after buying an additional 250 shares in the last quarter. Finally, Concorde Asset Management LLC boosted its position in Amgen by 21.7% in the third quarter. Concorde Asset Management LLC now owns 2,171 shares of the medical research company’s stock valued at $351,000 after buying an additional 387 shares in the last quarter. Institutional investors and hedge funds own 79.04% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.